In the BioHarmony Drug Report Database

"Preview" Icon

Olodaterol

Striverdi Respimat (olodaterol) is a small molecule pharmaceutical. Olodaterol was first approved as Striverdi Respimat on 2014-07-31. It is used to treat chronic bronchitis and pulmonary emphysema in the USA. The pharmaceutical is active against beta-2 adrenergic receptor. Striverdi respimat’s patents are valid until 2030-10-16 (FDA).

 

Trade Name

 

Striverdi Respimat
 

Common Name

 

olodaterol
 

ChEMBL ID

 

CHEMBL605846
 

Indication

 

chronic bronchitis, pulmonary emphysema
 

Drug Class

 

Bronchodilators (phenethylamine derivatives)

Image (chem structure or protein)

Olodaterol structure rendering